| 2.14 0.07 (3.38%) | 10-30 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.73 | 1-year : | 2.97 |
| Resists | First : | 2.34 | Second : | 2.54 |
| Pivot price | 2.21  |
|||
| Supports | First : | 2 | Second : | 1.67 |
| MAs | MA(5) : | 2.13 |
MA(20) : | 2.24 |
| MA(100) : | 2.44 |
MA(250) : | 3.41 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 14.6  |
D(3) : | 15.5 |
| RSI | RSI(14): 36.8 |
|||
| 52-week | High : | 11.65 | Low : | 1.87 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ALBT ] has closed above bottom band by 8.2%. Bollinger Bands are 63.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 12 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 2.11 - 2.13 | 2.13 - 2.14 |
| Low: | 2.01 - 2.03 | 2.03 - 2.04 |
| Close: | 2.07 - 2.1 | 2.1 - 2.13 |
Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and the People's Republic of China. The company offers medical related consulting services, including research studies, executive education, daily online executive briefings, tailored expert advisory services, and consulting and management services in the areas of immunotherapy and second opinion/referral services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells. It is also developing RNA-based FASH-CARTM cell therapy platform. In addition, the company develops avalon clinical-grade tissue-specific exosome (ACTEX); offers therapeutic and diagnostic targets utilizing QTY-code protein design technology with Massachusetts Institute of Technology (MIT), including using the QTY code protein design technology for development of a hemofiltration device to treat Cytokine Storm; and provides co-development of next generation, transposon-based, multi-target CAR-T, CAR-NK, and other immune effector cell therapeutic modalities with Arbele Limited. Further, it has strategic partnership with the University of Natural Resources and Life Sciences in Vienna and Austria to develop an S-layer vaccine that could be administered by an intranasal or oral route against SARS-CoV-2 and coronavirus that causes COVID-19 disease; and develops Avalon Cell and Avalon Rehab, as well as promotes standardization related to exosome industry. The company is headquartered in Freehold, New Jersey.
Mon, 28 Jul 2025
Avalon GloboCare Subsidiary Signs Distribution Agreement - TipRanks
Mon, 28 Jul 2025
Avalon GloboCare Enters into Distribution Agreement with Saga Health for KetoAir Targeting First Responders - Yahoo Finance
Wed, 23 Jul 2025
Avalon GloboCare enters agreement to sell $300,000 in Series C preferred stock - Investing.com
Mon, 14 Jul 2025
Avalon GloboCare Corp. Secures Patent for Proprietary CAR-T and CAR-NK Cell Technology in Hong Kong - Nasdaq
Mon, 14 Jul 2025
ALBT Shares Surge 12% Amidst Positive Market Momentum - StocksToTrade
Mon, 14 Jul 2025
Avalon GloboCare stock soars after securing new CAR-T cell patent - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Real Estate
|
|
|
Industry:
Real Estate - Services
|
|
| Shares Out | 0 (M) |
| Shares Float | 4 (M) |
| Held by Insiders | 3.36e+006 (%) |
| Held by Institutions | 12.4 (%) |
| Shares Short | 78 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -8.1e+006 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 109.5 % |
| Return on Equity (ttm) | -37.7 % |
| Qtrly Rev. Growth | 1.16e+006 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -5.13333e+007 |
| Qtrly Earnings Growth | -12.1 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -6 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.01 |
| Dividend | 0 |
| Forward Dividend | 98360 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|